<DOC>
	<DOCNO>NCT00148252</DOCNO>
	<brief_summary>To compare change renal function CsA MMF withdrawal 12 month drug withdrawal renal transplant recipient triple immunosuppressive therapy</brief_summary>
	<brief_title>Lowering Total Immunosuppressive Load Renal Transplant Recipients More Than 12 Months Posttransplant</brief_title>
	<detailed_description>To compare change renal function CsA MMF withdrawal 12 month drug withdrawal renal transplant recipient triple immunosuppressive therapy . Secondly examine safety follow withdrawal CsA MMF , respectively , follow parameter : - Biopsy verify acute rejection episode , time first rejection number steroid resistant rejection episode within 12 month . - Hematology ( Hb , WBC , platelet ) abnormality within 12 month . - Graft patient survival 12 month 5 year . Absolute difference renal function withdrawal group 12 month . Three monthly change renal function drug withdrawal 12 month . Change dyslipidemia frequency drug withdrawal 12 month . Change hypertension frequency drug withdrawal 12 month . Change glucose tolerance drug withdrawal 12 month . Cumulative incidence clinical infection result hospitalization within 12 month . Sub protocol also examine follow aspect : Cardiovascular : Homocysteine . Lipid peroxidation . Microvascular function vasoactive parameter Quality life ( QoL ) : ESRD SCL-TM , SF-36 ( short version ) EQ-5D ( GI-checklist extend ) questionnaire use . Pharmacoeconomical evaluation .</detailed_description>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>1 . Patients either gender 18 year age time randomisation . 2 . More twelve month posttransplant . 3 . Treated immunosuppressive protocol consist CsA , MMF steroid time discharge transplant clinic ( e.g . 3 month posttransplant ) . 4 . Kidney ( ) transplant recipient stable renal function ( Screatinine &lt; 300 umol/L average increase Screatinine &lt; 20 % last 6 month prior inclusion ) without treat clinically and/or biopsy proven acute rejection episode last 6 month prior inclusion . 5 . No previous steroid resistant acute rejection ( e.g . treat ATG/OKT3 ) . 6 . Not two steroid sensitive acute rejection posttransplant . 7 . Signed informed consent . 1 . PRA positivity &gt; 20 % . 2 . Concomitant therapy investigational drug prohibit medication specify protocol . 3 . Life expectancy less one year . 4 . Acute illness acute fungal , bacterial viral infection screening . 5 . Unable and/or unlikely follow study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Calcineurin</keyword>
	<keyword>reduction</keyword>
	<keyword>immunosuppression</keyword>
	<keyword>cyclosporine A</keyword>
	<keyword>mycophenolate mofetil</keyword>
</DOC>